ATYR
aTYR PHARMA INC
NASDAQ · Healthcare · Biotechnology · US
$0.37
−2.18%Sep 8, 2026, 15:00 UTC
DelveInsight published a market research report on the sarcoidosis treatment market, forecasting growth through 2036 and highlighting emerging therapies.
Sep 1, 2026, 20:36 UTC
aTyr Pharma provided an update on the expected timing of an FDA response to its protocol submitted in June 2026 for a planned Phase 3 study of efzofitimod in pulmonary sarcoidosis.
Source:Aug 7, 2026, 20:01 UTC
aTyr Pharma announced a corporate restructuring, including a workforce reduction of approximately 60%, to support its efzofitimod program in ILD.
Source: